{ "cik": 1579428, "cik_padded": "0001579428", "entityName": "Axsome Therapeutics, Inc.", "fiscal_years": [ { "accn": "0001193125-26-064267", "filed": "2026-02-23", "fiscal_year": 2025, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 480000.0, "cash": 322933000.0, "eps_diluted": -3.68, "free_cash_flow": -93885000.0, "net_income": -183174000.0, "operating_cash_flow": -93405000.0, "operating_income": -166762000.0, "revenue": 638496000.0, "stockholders_equity": 88295000.0, "total_assets": 689805000.0, "total_liabilities": 601510000.0 }, "period_end": "2025-12-31", "ratio_units": { "leverage": "ratio", "net_margin": "ratio", "operating_margin": "ratio", "revenue_growth_yoy": "ratio", "roa_avg2y": "ratio", "roa_period_end": "ratio", "roe_avg2y": "ratio", "roe_period_end": "ratio" }, "ratios": { "leverage": 6.812503539271759, "net_margin": -0.2868835513456623, "operating_margin": -0.26117939658196765, "revenue_growth_yoy": 0.6554513563896674, "roa_avg2y": -0.2911445017614994, "roa_period_end": -0.26554461043338334, "roe_avg2y": -2.5211478907163993, "roe_period_end": -2.074568208845348 } }, { "accn": "0001193125-26-064267", "filed": "2026-02-23", "fiscal_year": 2024, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 270000.0, "cash": 315353000.0, "eps_diluted": -5.99, "free_cash_flow": -128680000.0, "net_income": -287216000.0, "operating_cash_flow": -128410000.0, "operating_income": -280562000.0, "revenue": 385693000.0, "stockholders_equity": 57015000.0, "total_assets": 568498000.0, "total_liabilities": 511483000.0 }, "period_end": "2024-12-31", "ratio_units": { "leverage": "ratio", "net_margin": "ratio", "operating_margin": "ratio", "revenue_growth_yoy": "ratio", "roa_avg2y": "ratio", "roa_period_end": "ratio", "roe_avg2y": "ratio" }, "ratios": { "leverage": 8.971025168815224, "net_margin": -0.7446751691111843, "operating_margin": -0.7274231059417724, "revenue_growth_yoy": 0.42532520325203255, "roa_avg2y": -0.4965981807399108, "roa_period_end": -0.5052190157221309, "roe_avg2y": -2.316332784928546 } }, { "accn": "0001193125-26-064267", "filed": "2026-02-23", "fiscal_year": 2023, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 582000.0, "cash": 386193000.0, "eps_diluted": -5.27, "free_cash_flow": -145662000.0, "net_income": -239238000.0, "operating_cash_flow": -145080000.0, "operating_income": -231825000.0, "revenue": 270600000.0, "stockholders_equity": 190977000.0, "total_assets": 588236000.0, "total_liabilities": 397259000.0 }, "period_end": "2023-12-31", "ratio_units": { "leverage": "ratio", "net_margin": "ratio", "operating_margin": "ratio", "revenue_growth_yoy": "ratio", "roa_avg2y": "ratio", "roa_period_end": "ratio", "roe_avg2y": "ratio", "roe_period_end": "ratio" }, "ratios": { "leverage": 2.080140540483933, "net_margin": -0.8841019955654104, "operating_margin": -0.8567073170731707, "revenue_growth_yoy": 4.407998081419749, "roa_avg2y": -0.5202454681465503, "roa_period_end": -0.4067041119550657, "roe_avg2y": -1.5920913843072142, "roe_period_end": -1.2527058232143138 } }, { "accn": "0001193125-26-064267", "filed": "2026-02-23", "fiscal_year": 2022, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 702000.0, "cash": 200842000.0, "eps_diluted": -4.6, "free_cash_flow": -117213000.0, "net_income": -187134000.0, "operating_cash_flow": -116511000.0, "operating_income": -179799000.0, "revenue": 50037000.0, "stockholders_equity": 109556000.0, "total_assets": 331476000.0, "total_liabilities": 221920000.0 }, "period_end": "2022-12-31", "ratio_units": { "leverage": "ratio", "roa_avg2y": "ratio", "roa_period_end": "ratio", "roe_avg2y": "ratio", "roe_period_end": "ratio" }, "ratios": { "leverage": 2.025630727664391, "roa_avg2y": -0.8926848627090952, "roa_period_end": -0.564547659559063, "roe_avg2y": -2.9896714515085434, "roe_period_end": -1.7081127459929168 } }, { "accn": "0000950170-25-022457", "filed": "2025-02-18", "fiscal_year": 2021, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 308000.0, "cash": 86472854.0, "eps_diluted": -3.47, "free_cash_flow": -108534000.0, "net_income": -130403000.0, "operating_cash_flow": -108226000.0, "operating_income": -124707000.0, "stockholders_equity": 15631000.0, "total_assets": 87785058.0, "total_liabilities": 72154706.0 }, "period_end": "2021-12-31", "ratio_units": { "leverage": "ratio", "roa_avg2y": "ratio", "roa_period_end": "ratio", "roe_avg2y": "ratio" }, "ratios": { "leverage": 4.6161285906212015, "roa_avg2y": -0.9521268595448528, "roa_period_end": -1.4854805928361976, "roe_avg2y": -2.0151285696625045 } }, { "accn": "0000950170-24-019118", "filed": "2024-02-23", "fiscal_year": 2020, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 45891.0, "cash": 183876453.0, "eps_diluted": -2.77, "free_cash_flow": -78502460.0, "net_income": -102900600.0, "operating_cash_flow": -78456569.0, "operating_income": -99141328.0, "stockholders_equity": 113793000.0, "total_assets": 186134323.0, "total_liabilities": 72341414.0 }, "period_end": "2020-12-31", "ratio_units": { "leverage": "ratio", "roa_avg2y": "ratio", "roa_period_end": "ratio", "roe_avg2y": "ratio", "roe_period_end": "ratio" }, "ratios": { "leverage": 0.6357281555104444, "roa_avg2y": -0.5060468520967416, "roa_period_end": -0.5528297970063264, "roe_avg2y": -0.7035568306459254, "roe_period_end": -0.9042788220716563 } }, { "accn": "0001564590-21-009924", "filed": "2023-02-28", "fiscal_year": 2019, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 16121.0, "cash": 219966167.0, "free_cash_flow": -46391180.0, "net_income": -68345186.0, "operating_cash_flow": -46375059.0, "operating_income": -67245097.0, "stockholders_equity": 178722389.0, "total_assets": 220549760.0, "total_liabilities": 41827371.0 }, "period_end": "2019-12-31", "ratio_units": { "leverage": "ratio", "roa_avg2y": "ratio", "roa_period_end": "ratio", "roe_avg2y": "ratio", "roe_period_end": "ratio" }, "ratios": { "leverage": 0.23403542910340125, "roa_avg2y": -0.5793706979834728, "roa_period_end": -0.3098855605193132, "roe_avg2y": -0.7608267624607794, "roe_period_end": -0.38240976064839866 } }, { "accn": "0001558370-20-002573", "filed": "2022-03-01", "fiscal_year": 2018, "form": "10-K", "fundamental_units": { "capex": "USD", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 32696.0, "free_cash_flow": -30086397.0, "net_income": -30965464.0, "operating_cash_flow": -30053701.0, "operating_income": -32846577.0, "stockholders_equity": 937921.0, "total_assets": 15379279.0, "total_liabilities": 14441358.0 }, "period_end": "2018-12-31", "ratio_units": { "leverage": "ratio", "roa_avg2y": "ratio", "roe_avg2y": "ratio" }, "ratios": { "leverage": 15.397200830347119, "roa_avg2y": -1.215885322351931, "roe_avg2y": -3.5078121141351213 } }, { "accn": "0001564590-21-009924", "filed": "2021-03-01", "fiscal_year": 2017, "form": "10-K", "fundamental_units": { "capex": "USD", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 9898.0, "free_cash_flow": -26481550.0, "net_income": -28943392.0, "operating_cash_flow": -26471652.0, "operating_income": -27164307.0, "stockholders_equity": 16717223.0, "total_assets": 35555564.0, "total_liabilities": 18838341.0 }, "period_end": "2017-12-31", "ratio_units": { "leverage": "ratio", "roa_avg2y": "ratio", "roa_period_end": "ratio", "roe_avg2y": "ratio", "roe_period_end": "ratio" }, "ratios": { "leverage": 1.1268821980779942, "roa_avg2y": -0.784712192678436, "roa_period_end": -0.8140327066672322, "roe_avg2y": -1.5118513636695803, "roe_period_end": -1.7313516724637819 } }, { "accn": "0001558370-20-002573", "filed": "2020-03-12", "fiscal_year": 2016, "form": "10-K", "fundamental_units": { "capex": "USD", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 104561.0, "free_cash_flow": -21385865.0, "net_income": -27201653.0, "operating_cash_flow": -21281304.0, "operating_income": -27543508.0, "stockholders_equity": 21571451.0, "total_assets": 38212608.0, "total_liabilities": 16641157.0 }, "period_end": "2016-12-31", "ratio_units": { "leverage": "ratio", "roa_period_end": "ratio", "roe_period_end": "ratio" }, "ratios": { "leverage": 0.7714435621414619, "roa_period_end": -0.7118502092293727, "roe_period_end": -1.2610024703484248 } } ], "latest_filing": { "accn": "0001193125-26-064267", "filed": "2026-02-23", "form": "10-K" }, "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.", "schema_version": "1", "sic": "2834", "sic_description": "Pharmaceutical Preparations", "source_urls": { "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001579428.json", "sec_submissions": "https://data.sec.gov/submissions/CIK0001579428.json" }, "ticker": "AXSM" }